Homologous recombination-deficient cancers: approaches to improve treatment and patient selection

recruitment to stalled replication forks 47 . These data suggest that besides HR functionality, replication fork protection is critically involved in sensitivity to PARP inhibitors in BRCA2-deficient cancers.

[1]  Matthew J. Neale,et al.  Bidirectional resection of DNA double-strand breaks by Mre11 and Exo1 , 2011, Nature.

[2]  Kumar Somyajit,et al.  Mammalian RAD51 paralogs protect nascent DNA at stalled forks and mediate replication restart , 2020, Nucleic acids research.

[3]  J. Reis-Filho,et al.  Bi‐allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer , 2017, The Journal of pathology.

[4]  J. Bartek,et al.  Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress , 2017, Oncogene.

[5]  Alan Ashworth,et al.  PARP inhibitors: Synthetic lethality in the clinic , 2017, Science.

[6]  E. Birney,et al.  HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures , 2017, Nature Medicine.

[7]  Hiro Sato,et al.  BRCA1 Directs the Repair Pathway to Homologous Recombination by Promoting 53BP1 Dephosphorylation. , 2017, Cell reports.

[8]  P. Cejka,et al.  Phosphorylated CtIP Functions as a Co-factor of the MRE11-RAD50-NBS1 Endonuclease in DNA End Resection. , 2016, Molecular cell.

[9]  A. Richardson,et al.  CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. , 2016, Cell reports.

[10]  P. Kristel,et al.  Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer. , 2016, Journal of the National Cancer Institute.

[11]  Y. Pommier,et al.  Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action , 2016, Science Translational Medicine.

[12]  Ignace Vergote,et al.  Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.

[13]  S. Kaye,et al.  BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  C. Perou,et al.  Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts , 2016, Clinical Cancer Research.

[15]  Robert A. Baldock,et al.  Human BRCA1–BARD1 ubiquitin ligase activity counteracts chromatin barriers to DNA resection , 2016, Nature Structural &Molecular Biology.

[16]  S. Cantor,et al.  Replication Fork Stability Confers Chemoresistance in BRCA-deficient Cells , 2016, Nature.

[17]  Kelly S. Levano,et al.  Germline mutations of the DNA repair pathways in uterine serous carcinoma. , 2016, Gynecologic oncology.

[18]  T. Walsh,et al.  Inherited Mutations in Women With Ovarian Carcinoma. , 2016, JAMA oncology.

[19]  S. Kaye,et al.  PARP inhibitors: the race is on , 2016, British Journal of Cancer.

[20]  Jason Kaplan,et al.  Genomic landscape of DNA repair genes in cancer , 2016, Oncotarget.

[21]  Z. Szallasi,et al.  Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer , 2016, Clinical Cancer Research.

[22]  Grant W. Brown,et al.  HELB Is a Feedback Inhibitor of DNA End Resection. , 2016, Molecular cell.

[23]  Ayala Hubert,et al.  Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. , 2016, Gynecologic oncology.

[24]  Lara E Sucheston-Campbell,et al.  Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. , 2015, Journal of the National Cancer Institute.

[25]  Lara E Sucheston-Campbell,et al.  Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Schellens,et al.  Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer , 2015, British Journal of Cancer.

[27]  F. Couch,et al.  BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  Minjeong Park,et al.  Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, Arun BK and Litton JK. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015;121:269‐275. , 2015, Cancer.

[29]  Joshy George,et al.  Whole–genome characterization of chemoresistant ovarian cancer , 2015, Nature.

[30]  J. Reid,et al.  Characteristics of homologous recombination deficiency (HRD) in paired primary and recurrent high-grade serous ovarian cancer (HGSOC) , 2015 .

[31]  D. Durocher,et al.  MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5′ end-resection , 2015, Nature.

[32]  Peter Bouwman,et al.  REV7 counteracts DNA double-strand break resection and affects PARP inhibition , 2015, Nature.

[33]  Martin Kircher,et al.  Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. , 2015, Cancer discovery.

[34]  Ayala Hubert,et al.  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  R. Pomerantz,et al.  Mechanism of Microhomology-Mediated End-Joining Promoted by Human DNA Polymerase Theta , 2014, Nature Structural &Molecular Biology.

[36]  B. Monk,et al.  Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2. , 2014, Gynecologic oncology.

[37]  E. Kohn,et al.  Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. , 2014, The Lancet. Oncology.

[38]  D. Matei,et al.  Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial , 2014 .

[39]  Radhakrishnan Kanagaraj,et al.  DNA2 Cooperates with the WRN and BLM RecQ Helicases to Mediate Long-range DNA End Resection in Human Cells* , 2014, The Journal of Biological Chemistry.

[40]  E. Yang,et al.  An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer. , 2014, Gynecologic oncology.

[41]  D. Matei,et al.  Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[42]  A. Sieuwerts,et al.  Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment , 2014, Clinical Cancer Research.

[43]  A. Tutt,et al.  Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers , 2014, Breast Cancer Research.

[44]  Lori Minasian,et al.  Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. , 2014, Journal of the National Cancer Institute.

[45]  M. Loda,et al.  Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. , 2014, Cancer discovery.

[46]  S. Rodenhuis,et al.  Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy , 2014, Breast Cancer Research.

[47]  S. Lees-Miller,et al.  Non-homologous end joining: emerging themes and unanswered questions. , 2014, DNA repair.

[48]  W. Wiedemeyer,et al.  VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2. , 2014, Neoplasia.

[49]  S. Jackson,et al.  Transcriptionally active chromatin recruits homologous recombination at DNA double-strand breaks , 2014, Nature Structural &Molecular Biology.

[50]  R. West,et al.  brca2 and tp53 Collaborate in Tumorigenesis in Zebrafish , 2014, PloS one.

[51]  K. Cimprich,et al.  Causes and consequences of replication stress , 2013, Nature Cell Biology.

[52]  Y. Pommier,et al.  Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib , 2013, Molecular Cancer Therapeutics.

[53]  B. Blagoev,et al.  JMJD1C demethylates MDC1 to regulate the RNF8 and BRCA1–mediated chromatin response to DNA breaks , 2013, Nature Structural &Molecular Biology.

[54]  S. Powell,et al.  RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination , 2013, Oncogene.

[55]  A. Ashworth,et al.  BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency , 2013, Clinical Cancer Research.

[56]  J. Jonkers,et al.  A high-throughput functional complementation assay for classification of BRCA1 missense variants. , 2013, Cancer discovery.

[57]  R. Eeles,et al.  Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. , 2013, Journal of the National Cancer Institute.

[58]  Facundo D. Batista,et al.  RIF1 Is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break Resection , 2013, Molecular cell.

[59]  Adam P. Rosebrock,et al.  A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice. , 2013, Molecular cell.

[60]  M. Birrer,et al.  BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study , 2013, British Journal of Cancer.

[61]  C. V. van Asperen,et al.  Variants of Uncertain Significance in BRCA1 and BRCA2 assessment of in silico analysis and a proposal for communication in genetic counselling , 2012, Journal of Medical Genetics.

[62]  P. Pandolfi,et al.  Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. , 2012, Cancer discovery.

[63]  Y. Pommier,et al.  Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. , 2012, Cancer research.

[64]  P. Møller,et al.  The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers , 2012, British Journal of Cancer.

[65]  Lei He,et al.  PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. , 2012, Cancer discovery.

[66]  J. George,et al.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  Hong Wu,et al.  A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. , 2012, Cancer cell.

[68]  S. Smerdon,et al.  Plk1 and CK2 Act in Concert to Regulate Rad51 during DNA Double Strand Break Repair , 2012, Molecular cell.

[69]  M. Tarsounas,et al.  RAD51 paralogs: roles in DNA damage signalling, recombinational repair and tumorigenesis. , 2011, Seminars in cell & developmental biology.

[70]  H. Mackay,et al.  Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. , 2011, The Lancet. Oncology.

[71]  Rochelle L. Garcia,et al.  Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  Kwok-Kin Wong,et al.  COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION , 2011, Nature Medicine.

[73]  Stephen C. West,et al.  DNA interstrand crosslink repair and cancer , 2011, Nature Reviews Cancer.

[74]  Joshua E. Elias,et al.  A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers , 2011, Nature.

[75]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[76]  A. Egashira,et al.  Double-Strand Break Repair-Independent Role for BRCA2 in Blocking Stalled Replication Fork Degradation by MRE11 , 2011, Cell.

[77]  R. Kanaar,et al.  Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition , 2011, Proceedings of the National Academy of Sciences.

[78]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[79]  Paul Modrich,et al.  BLM-DNA2-RPA-MRN and EXO1-BLM-RPA-MRN constitute two DNA end resection machineries for human DNA break repair. , 2011, Genes & development.

[80]  Scott H. Kaufmann,et al.  Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells , 2011, Proceedings of the National Academy of Sciences.

[81]  Cristina Al-Khalili Szigyarto,et al.  Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate , 2010, Nucleic acids research.

[82]  M. J. van de Vijver,et al.  An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[83]  A. Ashworth,et al.  A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer , 2010, Clinical Cancer Research.

[84]  A. D’Andrea,et al.  Expanded roles of the Fanconi anemia pathway in preserving genomic stability. , 2010, Genes & development.

[85]  G. Mills,et al.  Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  M. Sivasubramaniam,et al.  Ku70 Corrupts DNA Repair in the Absence of the Fanconi Anemia Pathway , 2010, Science.

[87]  E. Kass,et al.  Loss of 53BP1 is a gain for BRCA1 mutant cells. , 2010, Cancer cell.

[88]  D. Adams,et al.  53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers , 2010, Nature Structural &Molecular Biology.

[89]  Jeremy M. Stark,et al.  53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks , 2010, Cell.

[90]  Y. Drew,et al.  Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors , 2010, Clinical Cancer Research.

[91]  O. Fernandez-Capetillo,et al.  Nuclear phosphoinositide 3-kinase β controls double-strand break DNA repair , 2010, Proceedings of the National Academy of Sciences.

[92]  Z. Szallasi,et al.  Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  M. Jasin,et al.  Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis , 2010, Nature Reviews Molecular Cell Biology.

[94]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[95]  J. Bartek,et al.  The DNA-damage response in human biology and disease , 2009, Nature.

[96]  Eric F. Johnson,et al.  Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways , 2009, Molecular Cancer Research.

[97]  C. Deng,et al.  A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. , 2009, Molecular cell.

[98]  N. Curtin,et al.  Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines , 2009, British Journal of Cancer.

[99]  C. Liao,et al.  RAD51C facilitates checkpoint signaling by promoting CHK2 phosphorylation , 2009, The Journal of cell biology.

[100]  R. Eeles,et al.  "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  J. Peterse,et al.  Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH , 2008, Breast Cancer Research and Treatment.

[102]  Jeremy M. Stark,et al.  Alternative-NHEJ Is a Mechanistically Distinct Pathway of Mammalian Chromosome Break Repair , 2008, PLoS genetics.

[103]  B. Karlan,et al.  Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. , 2008, Cancer research.

[104]  Ricky A. Sharma,et al.  DNA repair pathways as targets for cancer therapy , 2008, Nature Reviews Cancer.

[105]  F. Couch,et al.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.

[106]  M. Lieber,et al.  The Mechanism of Human Nonhomologous DNA End Joining* , 2008, Journal of Biological Chemistry.

[107]  Jiri Bartek,et al.  Human CtIP promotes DNA end resection , 2007, Nature.

[108]  Fergus J Couch,et al.  A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. , 2007, American journal of human genetics.

[109]  J. Peterse,et al.  Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer , 2007, Proceedings of the National Academy of Sciences.

[110]  Jos Jonkers,et al.  Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer , 2007, Proceedings of the National Academy of Sciences.

[111]  B. A. Ballif,et al.  ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage , 2007, Science.

[112]  R. Kanaar,et al.  DNA double-strand break repair: all's well that ends well. , 2006, Annual review of genetics.

[113]  George Iliakis,et al.  PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways , 2006, Nucleic acids research.

[114]  J. Jonkers,et al.  Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects , 2006, Oncogene.

[115]  A. Ashworth,et al.  The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability , 2006, Oncogene.

[116]  Alan Ashworth,et al.  Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. , 2006, Cancer research.

[117]  O. Mazina,et al.  Rad54 protein promotes branch migration of Holliday junctions , 2006, Nature.

[118]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[119]  J. Hoeijmakers,et al.  Fanconi Anemia (Cross)linked to DNA Repair , 2005, Cell.

[120]  R. Kanaar,et al.  Ionizing radiation-induced foci formation of mammalian Rad51 and Rad54 depends on the Rad51 paralogs, but not on Rad52. , 2005, Mutation research.

[121]  Yunmei Ma,et al.  Repair of Double-Strand DNA Breaks by the Human Nonhomologous DNA End Joining Pathway: The Iterative Processing Model , 2005, Cell cycle.

[122]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[123]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[124]  T. E. Wilson,et al.  New Insights into NHEJ Repair Processes in Prokaryotes , 2005, Cell cycle.

[125]  Junjie Chen,et al.  DNA Damage-Induced Cell Cycle Checkpoint Control Requires CtIP, a Phosphorylation-Dependent Binding Partner of BRCA1 C-Terminal Domains , 2004, Molecular and Cellular Biology.

[126]  Paul Lizardi,et al.  Down-Regulation of Rad51 and Decreased Homologous Recombination in Hypoxic Cancer Cells , 2004, Molecular and Cellular Biology.

[127]  N. Kasahara,et al.  Identification and Biochemical Characterization of a Werner's Syndrome Protein Complex with Ku70/80 and Poly(ADP-ribose) Polymerase-1* , 2004, Journal of Biological Chemistry.

[128]  Zhihui Feng,et al.  Chk2 Phosphorylation of BRCA1 Regulates DNA Double-Strand Break Repair , 2004, Molecular and Cellular Biology.

[129]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[130]  S. Elledge,et al.  53BP1, a Mediator of the DNA Damage Checkpoint , 2002, Science.

[131]  Douglas F Easton,et al.  Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.

[132]  O. Kallioniemi,et al.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. , 2002, American journal of human genetics.

[133]  Christos Sotiriou,et al.  Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. , 2002, Journal of the National Cancer Institute.

[134]  J. Kutok,et al.  Expression of geminin as a marker of cell proliferation in normal tissues and malignancies. , 2002, The American journal of pathology.

[135]  Hans Joenje,et al.  Biallelic Inactivation of BRCA2 in Fanconi Anemia , 2002, Science.

[136]  J. Benítez,et al.  Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer , 2002, International journal of cancer.

[137]  M. J. van de Vijver,et al.  The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  Nazneen Rahman,et al.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.

[139]  F. Alt,et al.  The Mechanism and Regulation of Chromosomal V(D)J Recombination , 2002, Cell.

[140]  S. Elledge,et al.  The BRCA1 suppressor hypothesis: an explanation for the tissue-specific tumor development in BRCA1 patients. , 2002, Cancer cell.

[141]  C. Deng,et al.  Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice , 2001, Oncogene.

[142]  M. Jasin,et al.  Sister chromatid gene conversion is a prominent double‐strand break repair pathway in mammalian cells , 2000, The EMBO journal.

[143]  Y. Shiloh,et al.  Functional link between ataxia-telangiectasia and Nijmegen breakage syndrome gene products , 2000, Nature.

[144]  D. Livingston,et al.  ATM phosphorylation of Nijmegen breakage syndrome protein is required in a DNA damage response , 2000, Nature.

[145]  J. Herman,et al.  Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. , 2000, Journal of the National Cancer Institute.

[146]  D. Fishman,et al.  BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. , 2000, American journal of human genetics.

[147]  S. Elledge,et al.  DNA damage-induced activation of p53 by the checkpoint kinase Chk2. , 2000, Science.

[148]  Jong-Soo Lee,et al.  hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response , 2000, Nature.

[149]  S. Lakhani.  The Pathology of Hereditary Breast Cancer , 1999, Disease markers.

[150]  G E Tomlinson,et al.  BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. , 1999, Cancer research.

[151]  J. Hoeijmakers,et al.  The Human Rad54 Recombinational DNA Repair Protein Is a Double-stranded DNA-dependent ATPase* , 1998, The Journal of Biological Chemistry.

[152]  J. Peto,et al.  p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours , 1998, Oncogene.

[153]  B. Ponder,et al.  Involvement of Brca2 in DNA repair. , 1998, Molecular cell.

[154]  L. Hartwell,et al.  Integrating genetic approaches into the discovery of anticancer drugs. , 1997, Science.

[155]  T. Mak,et al.  Brca2 is required for embryonic cellular proliferation in the mouse. , 1997, Genes & development.

[156]  T. Ludwig,et al.  Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. , 1997, Genes & development.

[157]  G. Eichele,et al.  Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2 , 1997, Nature.

[158]  J. Rossant,et al.  The Tumor Suppressor Gene Brca1 Is Required for Embryonic Cellular Proliferation in the Mouse , 1996, Cell.

[159]  J. Rommens,et al.  The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds , 1996, Nature Genetics.

[160]  Julian Peto,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1996, Nature.

[161]  B. Koller,et al.  Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities , 1996, Nature Genetics.

[162]  D. Ward,et al.  Nuclear foci of mammalian Rad51 recombination protein in somatic cells after DNA damage and its localization in synaptonemal complexes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[163]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[164]  M. Skolnick,et al.  BRCA1 mutations in primary breast and ovarian carcinomas. , 1994, Science.

[165]  S. Fields,et al.  Two cellular proteins that bind to wild-type but not mutant p53. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[166]  M. R. Purnell,et al.  Novel inhibitors of poly(ADP-ribose) synthetase. , 1980, The Biochemical journal.

[167]  J. Lucchesi.  Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanfgaster. , 1968, Genetics.

[168]  J. Lukas,et al.  TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity TOP BP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity , 2016 .

[169]  H. Mackay,et al.  Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. , 2015, The Lancet. Oncology.

[170]  P. Ang,et al.  Breast-cancer risk in families with mutations in PALB2. , 2014, The New England journal of medicine.

[171]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[172]  Lukas J A Stalpers,et al.  Inhibition of homologous recombination by hyperthermia shunts early double strand break repair to non-homologous end-joining. , 2013, DNA repair.

[173]  J. Thigpen.  Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer , 2012 .

[174]  Ricky A. Sharma,et al.  Molecular and Cellular Pathobiology Cancer Research Poly ( ADP-Ribose ) Polymerase Is Hyperactivated in Homologous Recombination – Defective Cells , 2010 .

[175]  S. Mitra,et al.  Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells , 2008, Cell Research.

[176]  H. Iwase,et al.  [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[177]  D. Schatz,et al.  The RAG proteins and V(D)J recombination: complexes, ends, and transposition. , 2000, Annual review of immunology.

[178]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[179]  B. Arun,et al.  Cancers Associated with Brca1 and Brca2 Mutations Other than Breast and Ovarian Cancers Associated with Brca1 and Brca2 Mutations Other than Breast and Ovarian , 2022 .